ClinicalTrials.Veeva

Menu

A Novel Selective Block of the Suprascapular Nerve

U

University Hospital of North Norway

Status and phase

Completed
Phase 4

Conditions

Fracture
Ligament Injury

Treatments

Procedure: LSIB + SSNB

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Patients who receive the lateral and sagittal infraclavicular block (LSIB) tend to supinate their hand and forearm which may hamper optimal positioning for surgery of the dorsal side of the hand. The investigators think that this supination is caused by lateral rotation in the shoulder. The main lateral rotator of the shoulder is the infraspinatus muscle, which is innervated by the suprascapular nerve (SSN).The investigators hypothesized that optimal positioning of the hand for surgery on the dorsal side of the hand may be achieved by performing a SSN block (SSNB) in addition to the LSIB.

Full description

According to the hypothesis the investigators will perform a double blind , placebo controlled study to answer the research question above.

Enrollment

30 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with American Society of Anesthesiologists physical status (ASA) I- III
  • age between 18 and 70 years
  • body mass index between 20 and 36 kg/m2 scheduled for elective hand surgery.

Exclusion criteria

We will measure the angle between wrist and horizontal plane while the patient is supine and the extended arm 75° abducted.

  • Patient who are not able to pronate the hand ≤15° before block performance, will be excluded from the study.
  • Patients will also be excluded if they are pregnant, have contraindications to regional anesthesia, coagulation disorder, allergy to local anesthetics (LA), atrioventricular block, peripheral neuropathy or drug-treated diabetes.
  • Patients using other anticoagulation drugs than acetylsalicylic acids or dipyridamol will be excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

30 participants in 2 patient groups, including a placebo group

LSIB +SSNB
Active Comparator group
Description:
Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
Treatment:
Procedure: LSIB + SSNB
LSIB + placebo
Placebo Comparator group
Description:
Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
Treatment:
Procedure: LSIB + SSNB

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems